---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-148067"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:02:07.121845+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience Q1 2022: FYARRO sales $2.3M; net loss $13.9M; first patient dosed in PRECISION 1 trial

## Summary
- Net product sales of FYARRO were $2.3M for partial first quarter since launch in Feb 2022.
- Net loss for Q1 2022 was $13.9M vs $5.5M in Q1 2021; operating expenses $16.1M vs $4.2M.
- Cash and equivalents $129.8M as of Mar 31, 2022, expected to fund operations into 2024.
- First patient dosed in PRECISION 1 Phase 2 tumor-agnostic trial for TSC1/TSC2 altered tumors; initial data expected H1 2023.
- Permanent J-code (J9331) for FYARRO granted, effective Jul 1, 2022; partnerships with Foundation Medicine and Tempus for trial enrollment.

## SEC filing metadata
- accession: 0001193125-22-148067
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312522148067/0001193125-22-148067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312522148067/d326757d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-148067
- JSON: https://secwatch.observer/filing/0001193125-22-148067.json
- Plain text: https://secwatch.observer/filing/0001193125-22-148067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.